Ascentage Pharma Group International ADR Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
41.7%projected annual EPS growth
Analyst Coverage
9analysts covering
FY EPS (est.)
-$0.21next fiscal year
Monitoring Framework
Key Performance Indicators
Olverembatinib China Product Sales Annually62.2M
Lisaftoclax China Product Sales Annually10.1M
Total Revenue Annually82.1M
Research and Development Expenses Annually
Watch Items
- POLARIS-1 Phase III trial readout for olverembatinib in first-line Ph+ ALLTrigger: Clinical trial completion and data lockAction: Prepare and submit New Drug Application (NDA) filings
- POLARIS-2 Phase III trial readout for olverembatinib in CMLTrigger: Clinical trial completion and data lockAction: Prepare and submit New Drug Application (NDA) filings
- GLORA-4 Phase III trial readout for lisaftoclax in first-line HR MDSTrigger: Clinical trial completion and data lockAction: Prepare and submit New Drug Application (NDA) filings
- Inclusion of Lisaftoclax in China's National Reimbursement Drug List (NRDL)Trigger: NRDL negotiation outcome announcementAction: Optimize commercial pricing and expand hospital formulary listings
Research as of 20 Jun 2026